Safety and Efficacy of Edoxaban in Non-Valvular Atrial Fibrillation Patients at high risk of bleeding in Korea

Chonnam National University Hospital0 个研究点目标入组 550 人开始时间: 待定最近更新: 2019年4月23日

适应症

试验速览

暂无简介。

•1. Patients over 18 years of age
•2. Patients with atrial fibrillation confirmed by ecg, holter, intracardiac devices within the past year
•3. CHA2DS2-VASc score = 2 points High-risk patients with an embolism stroke
•4. HAS BLED score = 3 points High-risk patients with bleeding
•5. Patients who voluntarily agreed to participate in clinical trials

•1. Reversible causes of atrial fibrillation patients
•2. Valvular atrial fibrillation patients
•3. Chronic renal failure or hemodialysis patients
•4. Patients with hypersensitive response to warfarin
•5. Patients with hypersensitive response to edoxaban
•6. Patients who are taking medications that are prohibited to co-use with warfarin
•7. Severe liver disease patients
•8. Minors, old man, pregnant woman
•9. Patients with increased risk of bleeding
•a. Bleeding history from the latest gastric ulcer
•b. Recent history of intracranial hemorrhage or intracranial hemorrhage
•c. Vascular malformation of spinal cord or cerebrovascular malformation
•d. Recent brain damage or spinal cord injury
•e. Recent brain surgery, spinal cord surgery, ophthalmic surgery
•f. Esophageal varix
•g. Arterovenous malformation
•h. Vascular aneurysm
•i. malignant tumor
•10. A combined treatment with other anticoagulants
•11. Uncontrolled severe hypertension patients
•12. pulmonary thromboembolism patients

发起方